{"product_id":"fulgentgenetics-five-forces-analysis","title":"Fulgent Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eFulgent's Porter’s Five Forces snapshot highlights intense competitive rivalry in diagnostics, moderate supplier power, strong buyer influence, and evolving threats from new entrants and substitutes as technology lowers barriers. This brief preview teases strategic implications. Unlock the full Porter's Five Forces Analysis to explore Fulgent’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated sequencing platform vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-generation sequencers are dominated by a few firms—Illumina, Thermo Fisher and BGI—with Illumina holding roughly two-thirds (≈66%) of the short-read market in 2024, concentrating supplier power. Switching platforms is costly due to validation, workflows and training, enabling vendors to set pricing, upgrade cadence and consumables lock-in. Long-term contracts and multi-vendor sourcing reduce, but do not remove, this leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary reagents and consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary reagents and consumables anchor platform ecosystems for Fulgent, making supplier disruptions critical; 2024 industry reports showed reagent price volatility and intermittent supply shocks—sometimes spiking costs by as much as 30%—that can lengthen turnaround times and compress margins. Bulk purchasing and tighter inventory practices mitigate risk but cold-chain and short shelf-life limit buffer stock to weeks. Co-development deals secure supply but increase supplier dependency and contractual exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCloud and bioinformatics infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScalable compute, storage and analytics for genomics depend on AWS\/Azure\/GCP (2024 market shares ~32%\/23%\/11%), creating supplier concentration. Egress fees (~$0.09\/GB) and specialized GPU demand (GPU instances 3–5x CPU cost) induce cost stickiness. Core algorithmic IP is internal, but pipelines use third-party toolchains and databases, while compliance and data residency rules significantly narrow vendor choice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-grade reference databases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical-grade reference databases boost clinical validity; ClinVar held \u0026gt;1.6M variant assertions in 2024. Proprietary sources (HGMD Pro ~USD2–5k\/yr) and subscription annotations raise supplier leverage and costs. Ancestry skew (\u0026gt;60% European in gnomAD 2024) necessitates supplemental partnerships; external curation cycles can delay updates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess improves clinical validity\u003c\/li\u003e\n\u003cli\u003eSubscription\/proprietary sources increase costs\u003c\/li\u003e\n\u003cli\u003eAncestry gaps require partnerships\u003c\/li\u003e\n\u003cli\u003eDependence on curation delays updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecimen collection and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecimen collection kit components and carrier performance directly affect sample integrity and throughput, with the global cold chain market surpassing 300 billion USD in 2024, highlighting logistics' strategic weight. Temperature-control materials and swab suppliers can bottleneck capacity, while fuel surcharges and route disruptions push up cost-to-serve and turnaround times. Diversified carriers and validated alternate kit parts reduce single-point failure risk and protect margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold chain market 2024 \u0026gt;300B USD\u003c\/li\u003e\n\u003cli\u003eFuel surcharges drive variable costs\u003c\/li\u003e\n\u003cli\u003eAlternate kit parts lower supply risk\u003c\/li\u003e\n\u003cli\u003eMultiple carriers improve resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier leverage: short-read leader \u003cstrong\u003e≈66%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: Illumina ≈66% short-read share (2024), reagent price shocks up to +30% and cold-chain market \u0026gt;300B USD (2024) concentrate leverage; cloud (AWS\/Azure\/GCP ~32\/23\/11%) and proprietary annotations (ClinVar \u0026gt;1.6M assertions) further limit alternatives, raising costs and switching barriers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier Area\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencers\u003c\/td\u003e\n\u003ctd\u003eIllumina ≈66%\u003c\/td\u003e\n\u003ctd\u003ePricing power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud\u003c\/td\u003e\n\u003ctd\u003eAWS\/Azure\/GCP ~32\/23\/11%\u003c\/td\u003e\n\u003ctd\u003eCost stickiness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\/Cold chain\u003c\/td\u003e\n\u003ctd\u003ePrice spikes ≤30%; market \u0026gt;$300B\u003c\/td\u003e\n\u003ctd\u003eMargin risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter’s Five Forces analysis for Fulgent that uncovers competitive intensity, buyer\/supplier power, threat of substitutes and entrants, and identifies disruptive trends and regulatory risks shaping its profitability and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eFulgent's Porter's Five Forces condenses competitive pressure into a single, customizable one-sheet with radar visuals—instantly adaptable to new data or scenarios and ready to drop into pitch decks or Excel dashboards for fast, boardroom-ready decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth systems and reference labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge health systems and reference labs concentrate buying power—by 2024 roughly two-thirds of U.S. hospitals belonged to multi-hospital systems—allowing aggregate volume discounts and demands for integration, custom reports and SLAs that raise switching costs while extracting price concessions. Consolidation across systems amplifies leverage across test menus; securing exclusive or preferred status can stabilize volumes but typically compresses margins and forces price and service concessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysicians and oncology practices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e2024 surveys show prescribers drive test choice by clinical utility, guideline inclusion and turnaround time, valuing robust evidence and support services; education and easy ordering increase loyalty but physicians will switch if alternatives demonstrate superior performance. Peer adoption and KOL endorsements remain key demand drivers, shaping ordering patterns across oncology practices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and reimbursement gatekeepers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCoverage decisions and prior authorization rules in 2024 continue to dictate realized pricing for Fulgent’s tests, with CMS MolDx and major commercial payers tightening criteria and reimbursement pathways. Payers push for lower rates, narrower indications, and outcomes evidence to limit spend. Lack of coverage shifts costs to patients and materially dampens demand. Demonstrating clinical utility and cost-effectiveness is essential to negotiate favorable policies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biopharma partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharma\/biopharma sponsors drive strong bargaining power: companion diagnostics and trial testing secure high-value contracts and, with over 60 FDA-cleared\/approved CDx by 2024, sponsors frequently demand bespoke assays, timelines and data rights that raise project complexity and margin pressure. Competitive bidding among labs gives sponsors price leverage, while long-term CDx partnerships can lock recurring revenue but require co-investment and regulatory commitments from both parties.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-value CDx deals\u003c\/li\u003e\n\u003cli\u003eOver 60 FDA CDx approvals (2024)\u003c\/li\u003e\n\u003cli\u003eSponsors demand bespoke assays\/data rights\u003c\/li\u003e\n\u003cli\u003eBidding drives price leverage\u003c\/li\u003e\n\u003cli\u003eLong-term CDx = locked revenue + co-investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-consumer and patient-paid segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect-to-consumer and patient-paid segments show high price elasticity when patients self-pay; the DTC genetic testing market was about $2.2 billion in 2023 and remains cost-sensitive as out-of-pocket buyers prioritize convenience, branding and data privacy. Transparent pricing and financing options expand access but raise price sensitivity as comparison shopping rises; regulatory clarity on DTC medical claims (FDA guidance updates through 2024) shapes demand and consumer expectations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice elasticity high for self-pay patients\u003c\/li\u003e\n\u003cli\u003e2023 DTC genetic testing market ≈ $2.2B\u003c\/li\u003e\n\u003cli\u003eConvenience, branding, data privacy drive choice\u003c\/li\u003e\n\u003cli\u003eTransparent pricing\/financing expand access yet increase sensitivity\u003c\/li\u003e\n\u003cli\u003e2024 regulatory clarity on DTC claims influences demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation and tighter coverage squeeze CDx pricing as sponsors and DTC push back\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge health systems concentrate buying power—by 2024 ~66% of U.S. hospitals in multi-hospital systems—driving volume discounts, integration demands and higher switching costs that compress margins.\u003c\/p\u003e\n\u003cp\u003ePayers and coverage rules (CMS MolDx + commercial) tightened in 2024, forcing narrower indications and lower realized prices absent strong utility evidence.\u003c\/p\u003e\n\u003cp\u003eSponsors (60+ FDA CDx by 2024) and price-sensitive DTC patients ($2.2B market 2023) exert opposing leverage: high-value CDx deals raise revenue but increase negotiation complexity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals in systems (2024)\u003c\/td\u003e\n\u003ctd\u003e~66%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA CDx approvals (2024)\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC genetic market (2023)\u003c\/td\u003e\n\u003ctd\u003e$2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eFulgent Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Fulgent Porter’s Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders. The document displayed is the final, fully formatted file ready for download and use the moment you buy. You're looking at the actual deliverable; upon payment you’ll get instant access to this same analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163198075257,"sku":"fulgentgenetics-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/fulgentgenetics-five-forces-analysis.png?v=1762716291","url":"https:\/\/portersfiveforce.com\/products\/fulgentgenetics-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}